Evidence map›Paper›PMID 39535353›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Cerebrovascular markers of WMH and infarcts in ADNI: A historical perspective and future directions.

Pauline Maillard, Evan Fletcher, Owen Carmichael, Christopher Schwarz, Stephan Seiler, Charles DeCarli, Alzheimer's Disease Neuroimaging Initiative

Abstract readReview
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Cerebrovascular markers of WMH and infarcts in ADNI: A historical perspective and future directions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pauline MaillardDepartment of Neurology, University of California at Davis, Sacramento, California, USA.
Evan FletcherDepartment of Neurology, University of California at Davis, Sacramento, California, USA.
Owen CarmichaelBiomedical Imaging, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, USA.
Christopher SchwarzDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Stephan SeilerDepartment of Neurology, University of California at Davis, Sacramento, California, USA.
Charles DeCarliDepartment of Neurology, University of California at Davis, Sacramento, California, USA.
Alzheimer's Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
UC Davis Alzheimer's Disease Research CenterP30AG072972 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Charles DeCarli, Rachel A Whitmer · 2021 to 2026
$25.2M
NIA NIH HHS P30 AG072972NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

White matter hyperintensities (WMH) and infarcts found on magnetic resonance imaging (MR infarcts) are common biomarkers of cerebrovascular disease. In this review, we summarize the methods, publications, and conclusions stemming from the Alzheimer's Disease Neuroimaging Initiative (ADNI) related to these measures. We combine analysis of WMH and MR infarct data from across the three main ADNI cohorts with a review of existing literature discussing new methodologies and scientific findings derived from these data. Although ADNI inclusion criteria were designed to minimize vascular risk factors and disease, data across all the ADNI cohorts found consistent trends of increasing WMH volumes associated with advancing age, female sex, and cognitive impairment. ADNI, initially proposed as a study to investigate biomarkers of AD pathology, has also helped elucidate the impact of asymptomatic cerebrovascular brain injury on cognition within a cohort relatively free of vascular disease. Future ADNI work will emphasize additional vascular biomarkers. HIGHLIGHTS: White matter hyperintensities (WMHs) are common to advancing age and likely reflect brain vascular injury among older individuals. WMH and to a lesser extent, magnetic resonance (MR) infarcts, affect risk for transition to cognitive impairment. WMHs and MR infarcts are present, even among Alzheimer's Disease Neuroimaging Initiative (ADNI) participants highly selected to have Alzheimer's disease (AD) as the primary pathology. WMH burden in ADNI is greater among individuals with cognitive impairment and has been associated with AD neurodegenerative markers and cerebral amyloidosis. The negative additive effects of cerebrovascular disease appear present, even in select populations, and future biomarker work needs to further explore this relationship.

Indexed as

Alzheimer DiseaseBrainMagnetic Resonance ImagingWhite MatterAgedBiomarkersCerebrovascular DisordersCognitive DysfunctionFemaleHumansMaleNeuroimagingBiomarkersAlzheimer's diseaseAlzheimer's Disease Neuroimaging Initiativecerebrovascular diseasemagnetic resonance infarctswhite matter hyperintensities

Identifiers

PMID39535353
PMCPMC11667517

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.